Adma Biologics reported $-13215000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adma Biologics ADMA:US $ -13.22M 1.62M
Agile Therapeutics AGRX:US $ -14.98M 6.8M
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
Dynavax Technologies DVAX:US $ 128.77M 96.32M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Novavax NVAX:US $ 216.06M 1037.12M
Takeda 4502:JP Y 308798M 158143M